Larazotide Capsules

Larazotide (also known as Larazotide Acetate or AT-1001) is a compounded oral peptide formulation designed to act locally within the gastrointestinal tract. It functions as a tight junction regulator, specifically targeting the intercellular tight junctions of the intestinal epithelium to modulate paracellular permeability. Tight Junction AssemblyLarazotide acts locally in the gastrointestinal tract to promote the assembly and closure of epithelial tight junctions. Intestinal Permeability ModulationLarazotide has been evaluated in peer-reviewed literature for its potential to mitigate increased intestinal permeability (often referred to as "leaky gut"). Oral Mucosal DeliveryLarazotide is formulated as an oral capsule to deliver the peptide directly to the intestinal mucosa with minimal systemic absorption. Macromolecule Translocation PathwaysLarazotide is associated with the modulation of pathways involved in the translocation of macromolecules across the intestinal barrier. Gastrointestinal Homeostasis SupportLarazotide has been studied for its potential utility in supporting gastrointestinal homeostasis in conditions characterized by compromised mucosal integrity. This product is intended for use by licensed healthcare providers in clinical settings. It is not intended for consumer sale. Buyer/doctor has determined and documented that the use of this product is appropriate for the patient based on the assessment of the patient's needs. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For professional use only.